Pomerantz Law Firm Launches Investigation for Vanda Pharmaceuticals Investors Following FDA Setback
On January 15, 2026, Pomerantz LLP announced that it is launching an investigation concerning Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on behalf of investors affected by recent troubling developments. This move comes in light of the company's disappointing press release from January 8, 2026, which informed the market about the U.S. Food and Drug Administration's (FDA) rejection of its supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) intended for treating jet lag disorder.
The FDA's decision, which was communicated in a detailed letter, noted positive results from Vanda's controlled clinical trials. However, regulators determined that these findings did not provide adequate evidence of effectiveness as they did not sufficiently mirror the real-world complexities of actual jet travel. These include critical factors like reduced oxygen pressure, physical constraints, noise, and changes in lighting, all of which are essential in assessing the drug's efficacy for jet lag treatment.
Following the FDA's announcement, Vanda’s stock price took a significant hit, plummeting by $1.20 to close at $7.34—a staggering decline of 14.05% in one day. Such a steep decrease indicates investor sentiment is heavily influenced by the FDA's devastating ruling.
Pomerantz LLP, a reputable law firm with a long standing history in securities class actions, is now urging affected investors to reach out for assistance. Danielle Peyton from the firm is coordinating the efforts to gather further information and will address inquiries from concerned investors. The law firm, established by Abraham L. Pomerantz—widely recognized as a pioneer in securities class action law—has been at the forefront of advocating for victims of corporate misconduct for over 85 years.
The firm has recovered substantial compensation for those who have suffered due to securities fraud, corporate fraud, and breaches of fiduciary duty. With offices across major cities, including New York, Chicago, and Tel Aviv, Pomerantz LLP continues its commitment to fighting for investor rights.
For investors who wish to join the investigation or learn more about their legal options, they can contact Danielle Peyton directly at [email protected] or by phone at 646-581-9980, ext. 7980.
This investigation serves as a crucial reminder of the potential risks in investing, especially in light of significant regulatory hurdles that can impact a company’s financial health and stock performance. Active participation in such investigations can empower investors and ensure that corporate transparency and integrity are upheld.
As the situation unfolds, it will be vital for investors to remain updated on any new developments regarding Vanda Pharmaceuticals and the outcomes of Pomerantz's investigation. Stakeholders must take proactive measures to safeguard their investments and seek redress for any losses sustained during this turbulent period. Staying informed and engaged with legal advisories can make all the difference in times of corporate uncertainty.
The FDA's decision, which was communicated in a detailed letter, noted positive results from Vanda's controlled clinical trials. However, regulators determined that these findings did not provide adequate evidence of effectiveness as they did not sufficiently mirror the real-world complexities of actual jet travel. These include critical factors like reduced oxygen pressure, physical constraints, noise, and changes in lighting, all of which are essential in assessing the drug's efficacy for jet lag treatment.
Following the FDA's announcement, Vanda’s stock price took a significant hit, plummeting by $1.20 to close at $7.34—a staggering decline of 14.05% in one day. Such a steep decrease indicates investor sentiment is heavily influenced by the FDA's devastating ruling.
Pomerantz LLP, a reputable law firm with a long standing history in securities class actions, is now urging affected investors to reach out for assistance. Danielle Peyton from the firm is coordinating the efforts to gather further information and will address inquiries from concerned investors. The law firm, established by Abraham L. Pomerantz—widely recognized as a pioneer in securities class action law—has been at the forefront of advocating for victims of corporate misconduct for over 85 years.
The firm has recovered substantial compensation for those who have suffered due to securities fraud, corporate fraud, and breaches of fiduciary duty. With offices across major cities, including New York, Chicago, and Tel Aviv, Pomerantz LLP continues its commitment to fighting for investor rights.
For investors who wish to join the investigation or learn more about their legal options, they can contact Danielle Peyton directly at [email protected] or by phone at 646-581-9980, ext. 7980.
This investigation serves as a crucial reminder of the potential risks in investing, especially in light of significant regulatory hurdles that can impact a company’s financial health and stock performance. Active participation in such investigations can empower investors and ensure that corporate transparency and integrity are upheld.
As the situation unfolds, it will be vital for investors to remain updated on any new developments regarding Vanda Pharmaceuticals and the outcomes of Pomerantz's investigation. Stakeholders must take proactive measures to safeguard their investments and seek redress for any losses sustained during this turbulent period. Staying informed and engaged with legal advisories can make all the difference in times of corporate uncertainty.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.